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to reduce the amount of virus in HIV-1-infected individuals.
Serum concentrations of DAB486 IL-2 used in the experiments described here (10-8 M) have been safely achieved in patients with IL-2R-expressing malignancies (16). Binding and internalization of DAB486 1L-2 by high-affinity IL-2R-bearing cells occurs within 30 min of exposure, resulting in maximal protein synthesis inhibition within 4 to 6 hours and cytotoxicity witiin 48 to 72 hours (24) . Therefore, despite the short serum half-life of DAB486 IL-2 (5 to 10 min), continuous administration of DAB486 IL-2 to patients should not be necessary.
Antitumor effects have been observed in refractory leukemia-lymphoma patients, and these effects have occurred despite the presence of antibodies to diphtheria toxin in some patients, and the presence of elevated soluble IL-2R levels in all patients. This observation is consistent with data obtained by ourselves and others that suggest that soluble IL-2Rs do not interfere with binding of IL-2 to the high-affinity IL-2R (25) . Table 2 . Incubation of T cell cultures with DAB486 IL-2-eliminated infectious virus. CD4+ T cells were infected with HIV-1, washed, and then mixed with uninfected cells 1 day later, as described in Table 1 . Mixtures (uninfected:infected T cells) are a ratio of 10:1. Cells were cultured in IL-2 (10-9 M), with and without DAB486 IL-2 (10-8 M) added on days 1 and 3. Cultures were washed and fed every 48 hours as described in Table 1 
Extensive immunological monitoring has been an important feature of early clinical trials, and patient data have demonstrated that DAB486 IL-2 has no generalized immunosuppressive properties (15, 16). The experimental results reported here indicate that DAB486 IL-2 selectively eliminates HIV-1-infected cells from mixed T cell cultures while sparing uninfected cells. In addition, DAB486 IL-2 inhibits production of viral proteins and infectious virus in T cells

sine kinase activity (4). FGF binding triggers intracellular phosphorylation of several proteins, including the receptors themselves, which may lead to FGF action (5).
Heparan sulfate binds bFGF with a dissociation constant of 10-8 to 10-M and is present on proteoglycans found in the extracellular matrix or anchored in the plasma membrane (2, 6, 7). An example of the latter is syndecan (8). Syndecan derived from several cell types, including NMuMG mammary epithelial cells, Swiss 3T3 cells, or MM14 myoblasts, binds to bFGF affinity columns (9, 10), and expression of syndecan in lymphoblastoid cells confers FGF binding on these cells (11) . Indirect roles for heparan sulfate in bFGF activity include extracellular stabilization and storage of FGF -(12, 13). A direct role in bFGF activity has not been apparent, although deletions of putative heparin or heparan sulfate binding regions from the growth factor dramatically reduce its biological activity (14) . Therefore, we have questioned whether a direct role exists for cell-surface heparan sulfate in the action of bFGF (10) .
Swiss 3T3 fibroblasts proliferate in response to FGF (15 88%, respectively (Fig. 1B) To directly question the importance of heparan sulfate-mediated binding to the action of bFGF, we examined the growth of Swiss 3T3 fibroblasts. The mitogenic response to 10 pM bFGF was inhibited by more than 90% if the cells were cultured in 30 mM chlorate, but it was restored by the addition of 10 mM sulfate (Fig. 3A) . Chlorate at 10 mM was less effective, consistent with its lesser effect on bFGF binding to heparan sulfate. We examined concentrations of bFGF up to 500 pM and found that chlorate inhibits bFGF-induced proliferation by more than 80%. Chlorate specifically inhibits bFGF action, as growth in 100 to 400 pM epidermal growth factor (EGF) (Fig. 3A) or 100 to 400 pM platelet-derived growth factor (19) was not affected. Furthermore, culturing cells simultaneously in 10 pM bFGF and 5 mIU heparitinase reduc,d 3H-labeled thymidine incorporation by 61% (19). Lastly, the chlorate blockage of bFGF-mediated growth could be overcome by exogenous heparin at concentrations as low as 1 ng/ml. This restoration not only demonstrates the ability of the cells to grow normally in chlorate, but also confirms the requirement of heparan sulfate or heparm for the action of bFGF.
The requirement for heparan sulfate also extends to the bFGF-mediated repression of MM14 skeletal muscle cell differentiation. assess the activation of muscle-spcific genes.
Treatment of MM14 cultures with chlorate reduces [3H]thymidine incorporation by 95% at concentrations of bFGF that promote maximal growth, and supplementing the sulfate concentration to 10 mM nullifies this inhibition (21). As occurs with the 3T3 cells, up to 90% of the specific binding of iodinated bFGF to cell surface receptors is abolished by treatment with either the sulfation inhibitor or heparitinase (21)
. These effects on proliferation were visualized directly by fluorescent staining of BrdU incorporation into newly synthesized DNA (Fig. 4A) . In addition, staining for myosin heavy chain in companion cultures showed that proliferating myoblasts remained as single, myosin-negative cells (Fig.  4E) . However, if the cells were cultured with bFGF in the presence of bFGF neutralizing antibodies (22), over 95% of the cells failed to incorporate BrdU, stained for muscle-specific myosin, and fused to form myo- tubes (Fig. 4, B and F) . This differentiation program was similarly initiated by culture in 30 mM chlorate,) despite the continued presence of bFGF (Fig. 4, C and G) . Simultaneous addition of chlorate and 10 mM sulfate restored bFGF signaling and prevented differentiation (Fig. 4, D To identify a sequence-specific binding site, cloned DNA sequences were screened by means of an immunoprecipitation technique (11, 12).. Two classes of clones were tested. The first consisted of 400 clones containing inserts of 300 to 1000 bp obtained randomly from the human genome. The second class consisted of cosmid and plasmid clones chosen because they contained sequences that might be important in normal growth control (12). Each clone was digested with an appropriate restriction endonuclease, end-labeled with 32p, and incubated with p53 from a lysate of cells infected with a recombinant vaccinia virus expressing p53 (11). Labeled DNA fragments that bound to p53 were then recovered by immunoprecipitation with monoclonal antibodies against p53 (anti-p53). Of the more than 1400 restriction fiagments tested, only two, both from the second class of clones, bound reproducibly to p53 under the experimental conditions used: a 259-bp Hinf I fragment (fragment A) of clone 772 CBE (Fig. IA, panel 2) , and a 190-bp Hinf I fragment (fragment B) of clone X 5R (Fig.  IA, panel 3) ; these fragments bound to a far greater extent (at least tenfold more) than any of the other labeled fragments of larger or smaller size present in the same assay mixes.
Subsequent efforts were concentrated on fragment A. First, it was demonstrated that detection of the binding of fragment A was dependent on both p53 protein and antip53. Lysates from cells infected with wildtype vaccinia virus (devoid of p53) were not able to specifically immunoprecipitate fragment A (Fig. IB) . Similarly, the precipitation of fiagment A was dependent on the presence of anti-p53 (Fig. IB) 
